Sanofi India Ltd - 500674 - Compliance Certificate - Regulation 7(3) Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
Pursuant to Regulation 7(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed the compliance certificate for the period 1st April 2020 to 30th September 2020. Sanofi India Ltd - 500674 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Link Intime India Private Limited, Registrar and Share Transfer Agent (RTA) of the Company has provided the enclosed certificate for the quarter ended 30th September 2020 under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018. Sanofi India Ltd - 500674 - Board Meeting Intimation for Meeting Of Board Of Directors To Be Held On 27Th October 2020
Sanofi India Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 27/10/2020 ,inter alia, to consider and approve Pursuant to Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that the meeting of the Board of Directors of the Company will be held on Tuesday, 27th October 2020; inter alia to consider the unaudited financial results for the quarter and nine months ended 30th September 2020 (Q3). Sanofi India Ltd - 500674 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Pursuant to Regulation 39 (3) of SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015, we would like to inform you that the Company has issued duplicate share certificates in lieu of the original share certificates reported lost/misplaced, details of which are enclosed. Sanofi India Ltd - 500674 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Pursuant to Regulation 39 (3) of SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015, we would like to inform you that the Company has received communication from its Registrar and Share Transfer Agent on loss of share certificate(s), details of which are enclosed. Sanofi India Ltd - 500674 - Regulation 30(5) Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
As required under regulation 30(5) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Board of Directors has authorised the Managing Director and Chief Financial Officer to determine materiality of an event or information in line with the said Regulations. The Board has also authorised the Company Secretary to disclose such information to the Stock Exchanges. The contact details of the above officials are enclosed. Sanofi India Ltd - 500674 - Appointment Of Chief Financial Officer
Dear Sirs, As required under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that the Board of Directors of the Company at its meeting held on 5th October 2020 approved appointment of Mr. Vaibhav Karandikar as Chief Financial Officer and Key Managerial Personnel with effect from 6th October 2020. A brief profile of Mr. Vaibhav Karandikar is enclosed. Please take the above information on record. GlaxoSmithKline CEO optimistic Covid-19 vaccine widely available in 2021
The group's most advanced project is with French partner Sanofi and the two have said they hope to get approval for their candidate next year Sanofi India Ltd - 500674 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Pursuant to Regulation 39 (3) of SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015, we would like to inform you that the Company has received communication from its Registrar and Share Transfer Agent on loss of share certificate(s), details of which are enclosed. Sanofi India Ltd - 500674 - Announcement under Regulation 30 (LODR)-Resignation of Chief Financial Officer (CFO)
As required under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that Mr. Charles Billard, Chief Financial Officer and Whole Time Director of the Company will relocate outside of India to take up a new role within Sanofi group. He will therefore step down as the Chief Financial Officer and Whole Time Director of the Company with effect from the end of the day on 30th September 2020. He will cease to be the Key Managerial Personnel of the Company with effect from the end of the day on 30th September 2020. The Board of Directors of the Company on 16th September 2020 approved resignation of Mr. Charles Billard as the Chief Financial Officer and Whole Time Director. Mr. Charles Billard will however continue to be engaged with the Company as a Non-Executive Director.